Friday, 30 September 2016

Gilead's Growth Tonic Is Elusive, May Have Side Effects

The biotech company’s deliberate approach to deal making has frustrated investors, but it could still pay off.

from WSJ.com: Markets http://ift.tt/2cH4nua
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)